The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development
批准号:
8517185
负责人:
CRAIG LINDSLEY
金额:
$264.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-01 至 2015-05-31
关键词:
Advanced DevelopmentArtsBiologicalBiological FactorsBiological Neural NetworksChemicalsChemistryClinicCollaborationsCommunitiesComputer SimulationComputer softwareCoupledDevelopmentDevelopment PlansDoctor of PhilosophyDrug IndustryEducational process of instructingElementsEnsureEquipmentEvaluationExerciseFamilyGoalsGuidelinesHigh Pressure Liquid ChromatographyHomology ModelingHuman ResourcesIn VitroIndustryInformaticsIon ChannelLeadLearningLibrariesLigandsLipaseMeasuresMedicalMissionModelingMolecularMolecular BankNational Institute of Mental HealthOffice of Administrative ManagementOrganic SynthesisPharmaceutical ChemistryPharmacologyPhosphotransferasesPreparationProductivityProgram DevelopmentPropertyQuantitative Structure-Activity RelationshipResearchResearch InfrastructureResearch PersonnelResearch Project GrantsResourcesSamplingServicesStructureSynthesis ChemistryTechniquesTechnologyTherapeutic AgentsTimeLineTrainingTriageUnited States National Institutes of HealthWorkbasecheminformaticscomputational chemistrydesigndrug discoveryexperienceimprovedin vivokillingsmedical specialtiesmeetingsmembermicrowave electromagnetic radiationnovelprogramsresearch studyscaffoldscale upscreeningtoolvirtual
中文摘要
我们建议建立一个专门的化学中心,即加速探针开发的范德比尔特专门化学中心,以加快发现和开发高质量的探针化合物,这将对MLPCN研究网络的目标产生重大影响。基于Lindsley技术支持合成(TES)实验室和Conn实验室的基础设施,资源和广泛的药物发现(从概念到临床的击中到导致证明)经验,我们准备与MLPCN网络中的外部专业筛选和综合中心合作支持探针开发项目。由于我们的高通量药物化学技术平台和我们的M.S.和博士我们建议的中心将能够支持五(5)个探针开发项目,与内部或外部中心并行(约20个探针开发项目/年),并需要不到三个月的时间来开发探针和先进的分子工具,用于体外和/或体内概念验证实验。拟议的范德比尔特加速探针开发专业化学中心与其他中心不同,因为PI在制药行业拥有8年的从点击到引线到概念验证的经验,并在范德比尔特内按照行业标准建立了一个设备齐全的高通量合成和纯化实验室,这使得最少的人力资源能够快速开发探针化合物。我们的最初目标是提供满足或超过MPLCN指南和/或满足启动筛选的研究者的探针的特定要求的探针化合物。当与NIH/NIMH和MLPCN目标保持一致时,我们将使用部分MLPCN和Lindsley和Conn实验室的内部资源(合成/药物化学,药理学,DMPK和放射化学)在中心-推动研究项目,进一步完善和开发治疗相关靶点的探针,以确保可以进行体内概念验证实验,以提供“快速杀灭”或验证靶点作为潜在治疗剂未满足的医疗需求。最后,我们将为MLPCN内的其他化学家提供培训休假,以学习并行合成技术和库设计策略。
英文摘要
We are proposing the establishment of a specialized chemistry center, the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, to expedite the discovery and development of high quality probe compounds which will significantly impact the goals of the MLPCN Research Network. Building on the infrastructure, resources and broad drug discovery (hit-to-lead-to-proof of concept-to-clinic) experience within the Lindsley Technology Enabled Synthesis (TES) Lab and the Conn Lab, we are poised to support probe development projects in collaboration with external Specialty Screening and Comprehensive Centers in the MLPCN Network. Due to our state-of-the-art technology platform for high-throughput medicinal chemistry and our M.S. and Ph.D. level staff chemists, our proposed center will be capable of supporting five (5) probe development projects, with internal or external centers, in parallel (~20 probe development programs/year) and require less than three months to develop probes and advanced molecular tools for in vitro and/or in vivo proof of concept experiments. The proposed Vanderbilt Specialized Chemistry Center for Accelerated Probe Development is unique from other centers in that the PI has eight years hit-to-lead-to-proof of concept experience in the pharmaceutical industry and has built a fully equipped high-throughput synthesis and purification lab, at the industry standard, within Vanderbilt which allows minimal human resources to develop probe compounds with expedited timelines. Our initial goal will be to deliver probe compounds that meet or exceed MPLCN guidelines and/or meet specific requirements for a probe of the investigator that initiated the screen. When aligned with NIH/NIMH and MLPCN goals, we will use a portion of our MLPCN and internal resources in the Lindsley and Conn Labs (synthesis/medicinal chemistry, pharmacology, DMPK and adiochemistry) in Center-Driven Research Projects to further refine and develop probes for therapeutically relevant targets to ensure in vivo proof of concept experiments can be performed to provide 'quick kills' or validate targets as potential therapeutic agents for unmet medical needs. Finally, we will offer training sabbaticals to other chemists within the MLPCN to learn parallel synthesis techniques and library design strategies.
期刊论文(53)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.tetlet.2015.01.140
发表时间:
2015-03-04
期刊:
Tetrahedron letters
影响因子:
1.8
作者:
[Senter TJ, O'Reilly MC, Chong KM, Sulikowski GA, Lindsley CW]
通讯作者:
Lindsley CW
Discovery of potent and selective GIRK1/2 modulators via 'molecular switches' within a series of 1-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)ureas.
通过一系列 1-(3-环丙基-1-苯基-1H-吡唑-5-基)脲中的“分子开关”发现有效且选择性的 GIRK1/2 调节剂。
DOI:
10.1016/j.bmcl.2014.08.061
发表时间:
2014
期刊:
Bioorganic & medicinal chemistry letters
影响因子:
2.7
作者:
[Wen,Wandong, Wu,Wenjun, Weaver,CDavid, Lindsley,CraigW]
通讯作者:
Lindsley,CraigW
Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.
M1 毒蕈碱乙酰胆碱受体亚型在基底神经节功能调节中的作用及其对帕金森病治疗的影响。
DOI:
10.1124/jpet.111.187856
发表时间:
2012
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
[Xiang,Zixiu, Thompson,AnalisaD, Jones,CarrieK, Lindsley,CraigW, Conn,PJeffrey]
通讯作者:
Conn,PJeffrey
Total synthesis of stemaphylline N-oxide and related C9a-epimeric analogues.
茎茶碱 N-氧化物和相关 C9a-差向异构类似物的全合成。
DOI:
10.1002/chem.201302669
发表时间:
2013
期刊:
Chemistry (Weinheim an der Bergstrasse, Germany)
影响因子:
--
作者:
[Schulte,MichaelL, Turlington,MarkL, Phatak,SharangdharS, Harp,JoelM, Stauffer,ShaunR, Lindsley,CraigW]
通讯作者:
Lindsley,CraigW
Optimization of a small molecule probe that restores e-cadherin expression.
恢复 e-钙粘蛋白表达的小分子探针的优化。
DOI:
10.1016/j.bmcl.2015.07.104
发表时间:
2015
期刊:
Bioorganic & medicinal chemistry letters
影响因子:
2.7
作者:
[Brogan,JohnT, Stoops,SydneyL, Brady,Suzanne, An,Hanbing, Weaver,Connie, Daniels,JScott, Beauchamp,RDaniel, Lindsley,CraigW, Waterson,AlexG]
通讯作者:
Waterson,AlexG
共 27 条
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
-
批准号:10426338
-
项目类别:
-
资助金额:$69.49万
-
财政年份:2020
-
负责人:CRAIG LINDSLEY
-
依托单位:
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
-
批准号:10674501
-
项目类别:
-
资助金额:$69.77万
-
财政年份:2020
-
负责人:CRAIG LINDSLEY
-
依托单位:
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
-
批准号:10093390
-
项目类别:
-
资助金额:$74.11万
-
财政年份:2020
-
负责人:CRAIG LINDSLEY
-
依托单位:
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
-
批准号:10266776
-
项目类别:
-
资助金额:$69.51万
-
财政年份:2020
-
负责人:CRAIG LINDSLEY
-
依托单位:
Allosteric modulators of the glucagon-like peptide-1 receptor
-
批准号:8996184
-
项目类别:
-
资助金额:$16.87万
-
财政年份:2014
-
负责人:CRAIG LINDSLEY
-
依托单位:
Center base project #2
-
批准号:8189624
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Medicinal Chemistry
-
批准号:7988517
-
项目类别:
-
资助金额:$63.5万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Chemistry Core
-
批准号:8139981
-
项目类别:
-
资助金额:$331.86万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Center base project #1
-
批准号:8189623
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Administrative Core
-
批准号:8139980
-
项目类别:
-
资助金额:$26.82万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction
-
批准号:7347914
-
项目类别:
-
资助金额:$42.83万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development
-
批准号:8139983
-
项目类别:
-
资助金额:$518.84万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:8706961
-
项目类别:
-
资助金额:$39.23万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:9250204
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:7625071
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction
-
批准号:8071079
-
项目类别:
-
资助金额:$39.86万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:8260205
-
项目类别:
-
资助金额:$34.19万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction
-
批准号:8262403
-
项目类别:
-
资助金额:$39.44万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:8503224
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction
-
批准号:7629161
-
项目类别:
-
资助金额:$42.5万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Handbook of the Mathematics of the Arts and Sciences的中文翻译
-
批准号:12226504
-
项目类别:数学天元基金项目
-
资助金额:20.0万元
-
批准年份:2022
-
负责人:黄朝凌
-
依托单位:
ARTS在邻苯二甲酸(2-乙基己基)酯诱导的小鼠睾丸间质细胞凋亡中的作用及机理研究
-
批准号:--
-
项目类别:--
-
资助金额:35万元
-
批准年份:2020
-
负责人:陈加祥
-
依托单位:
ARTS在邻苯二甲酸(2-乙基己基)酯诱导的小鼠睾丸间质细胞凋亡中的作用及机理研究
-
批准号:82060278
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2020
-
负责人:陈加祥
-
依托单位:
促进肿瘤凋亡的融合蛋白CPP-TRAIL-ARTS C27的制备及机制研究
-
批准号:81372444
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2013
-
负责人:易成
-
依托单位:
雄性锹甲的生殖对策抉择ARTs及其进化机制-基于行为与SSRs标记的整合研究
-
批准号:31201745
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2012
-
负责人:万霞
-
依托单位: